MassVX

Spinout with a MassVX Entrepreneurial Champion!

“Bring on a business expert so you can successfully lead the science.” – David Walt, an Entrepreneurial PI, Scientific Founder of Illumina, Inc., Quanterix Corp. and several other life sciences startups. Dave is a member of the faculty at Harvard Medical School, and a Howard Hughes Medical Institute Professor.

MassVX is our new, online platform that expedites academic spin-outs by curating matches between selected academic innovators with a MassVX Entrepreneurial Champion.

We’re Moving Beyond Mentoring.   

1. How we help academic innovators

If you are an academic founder who is 1) ready to expedite your spinout with a MassVX Entprepreneurial Champion 2) prefers to be the science and technology lead and 3) has proof-of-concept funding, contact us.

Tell me who you are, what you’re working on and your ask. MassVX Application

If accepted, we’ll curate a match and make the introduction.

2. Want to be an Entrepreneurial Champion and lead a spinout?

We’re intentionally using the term MassVX Entrepreneurial Champion to keep the business lead role flexible.  Depending on the match, you could be the Entrepreneurial Chairperson, an Executive Chair, or the CEO.

When an academic spinout opportunity arises that matches your interests and business skills, I’ll send you an invite to view their materials. You decide if you’d like to engage.  We understand it all depends on timing.

We’re always looking to work with the best Entrepreneurial Champions. Please contact Susan Ahern, Director of MassVX at Susan@MassVX.org

3. How Does MassVX Work?

Curate a Match + Build Trust

MassVX Partners and Collaborators

MassVX Traction since our Launch

  • Collaborating with leading scientist/inventors including:
    • Dr. Bob Langer at MIT.
      Dr. Langer’s patents have been licensed or sublicensed to over 400  pharmaceutical, chemical, biotechnology and medical device companies.  Dr. Langer has received over 220 major awards.   He is one of 4 living individuals to have received both the United States National Medal of Science (2006) and the United States National Medal of Technology and Innovation (2011).  He also received the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, the 2008 Millennium Prize, the world’s largest technology prize, the 2012 Priestley Medal, the highest award of the American Chemical Society, and the 2014 Breakthrough Prize in Life Sciences. In 2015, Dr. Langer received the Queen Elizabeth Prize for Engineering.
    • Dr. George Church at Harvard/Wyss
    • George helped initiate the Human Genome Project in 1984 and the Personal Genome Project in 2005. His many innovations have been the basis for a number of companies including Editas (Gene therapy); Gen9bio (Synthetic DNA); and Veritas Genetics (full human genome sequencing). George leads Synthetic Biology at the Wyss Institute. Among his recent work at the Wyss is development of a technology for synthesizing whole genes, and engineering whole genomes, far faster, more accurate, and less costly than current methods. George is widely recognized for his innovative contributions to genomic science and his many pioneering contributions to chemistry and biomedicine.
  • Gained the support of all 34 MA academic/research institutions, the entrepreneurial community including:
  • NovoNordisk
  • Boehgringer Ingelheim
  • Johnson & Johnson Innovation
  • Lily Pharmaceuticals
  • Sumitomo
  • Mass Life Science Center
  • MassBio
  • MassMedic
  • Launched beta with:
    • 400 Entrepreneurial Champions identified
    • a dozen academic projects on the platform
  • Created a MassVX Committee that includes:
    • Greg Erman, President and CEO, EmpiraMed, Inc.
    • Erika Bechtold, PhD., Director of Technology Commercialization, Wyss Institute
    • Leslie Williams, Founder, President & CEO, ImmusanT
    • Nancy Briefs, President & CEO, AltrixBio
    • Paul Hartung, Board Member, Leuko
    • Wan li Zu, Partner, Fairhaven Capital
    • Alan Kopin, Physician Scientist, Co-Founder, CSO, On Target Therapeutics

Our Mission

To provide a bit of context, Vinit, the new ED created a new mission: Enabling and celebrating Massachusetts to lead the nation in translating basic research to the market. I joined Vinit in May to help keep MA number one in innovation by supporting passionate academic innovators and collaborating with our state’s fantastic entrepreneurial business leaders.

MassVX is complimentary to, but different than, other great entrepreneurial and mentoring programs in our ecosystem. We are positioning ourselves to be the next step for the academic founders who prefer to be the scientific and technology leads.

For selection into MassVX, both the academic innovator and the Entrepreneurial Champion needs to meet certain criteria.


Spinout with us!

Top